Coagulation and liver transplantation

International Anesthesiology Clinics

Volumn 44, Issue 4, 2006, Pages 17-36

  Kang, Yoogoo ^a   Audu, Paul ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN ACETATE; HEPARIN LYASE; LYSINE DERIVATIVE; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ANAPHYLAXIS; BLOOD CLOTTING; HUMAN; KIDNEY INJURY; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG EMBOLISM; PATHOPHYSIOLOGY; PEROPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SUBSTITUTION THERAPY; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; HEMOSTASIS, SURGICAL; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MONITORING, INTRAOPERATIVE;

EID: 33749612874     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000210811.77663.1e     Document Type: Review

References (65)

1. Mammen EF. Coagulation defects in liver disease. Med Clin N Am. 1994;78:545-554.
2. Ballard HS, Marcus AJ. Platelet aggregation in portal cirrhosis. Arch Intern Med. 1976;136:316-319.
3. Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg. 1985;64:888-896.
4. Thomas DP, Ream VJ, Stuart RK. Platelet aggregation in patients with Laennec's cirrhosis of the liver. N Engl J Med. 1967;276:1344-1348.
5. Martinez J, Palascak JE, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest. 1978;61:535-538.
6. Green G, Thomson JM, Dymock IW, et al. Abnormal fibrin polymerisation in liver disease. Br J Haematol. 1976;34:425-439.
7. Green AJ, Ratnoff OD. Elevated antihemophilic factor (AHF, factor VIII) procoagulant activity and AHF-like antigen in alcoholic cirrhosis of the liver. J Lab Clin Med. 1974;83:189-197.
8. Tyagt G, Collen D, DeBreker RR, et al. Investigators on the fibrinolytic system in liver cirrhosis. Acta Haematol (Basel). 1968;40:265-274.
9. Von Kaulla KN, Kaye H, Von Kaulla E, et al. Changes in blood coagulation, before and after hepatectomy or transplantation in dogs and man. Arch Surg. 1966;92:71-79.
10. Groth CG, Pechet L, Starzl TE. Coagulation during and after orthotopic transplantation of the human liver. Arch Surg. 1969;98:31-34.
11. Owen CA Jr, Rettke SR, Bowie EJW, et al. Hemostatic evaluation of patients undergoing liver transplantation. Mayo Clin Proc. 1987;62:761-772.
12. Lewis JH, Bontempo FA, Awad SA, et al. Liver transplantation: intraoperative changes in coagulation factors in 100 first transplants. Hepatology. 1989;9:710-714.
13. Kratzer MAA, Dieterich J, Denecke H, et al. Hemostatic variables and blood loss during orthotopic human liver transplantation. Transplant Proc. 1991;23:1906-1911.
14. Kang Y, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology. 1987;66:766-773.
15. Porte RJ, Bontempo FA, Knot EA, et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation. 1989;47:978-984.
16. Groth CG, Pechet L, Starzl TE. Coagulation during and after orthotopic transplantation of the human liver. Arch Surg. 1969;98:31-34.
17. Virji MA, Aggarwal S, Kang Y. Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation. Transplant Proc. 1989;21(suppl 3):3540-3541.
18. Himmelreich G, Dooijewaard G, Breinl P, et al. Changes in urokinase-type plasminogen activator in orthotopic liver transplantation. Semin Thromb Hemost. 1993;19:311-314.
19. Lewis JH, Bontempo FA, Ragni MV, et al. Antithrombin III during liver transplantation. Transplant Proc. 1989;21:3543-3544.
20. Böhgmig HJ. The coagulation disorder of orthotopic hepatic transplantation. Semin Thromb Hemost. 1977;4:57-82.
21. Riess H, Jochum M, Machliedt W, et al. Possible role of extracellulary released phagocyte proteinase in the coagulation disorder during liver transplantation. Transplantation. 1991;52:482-490.
22. Starzl TE, Marchioro TL, von Kaulla KN, et al. Homotransplantation of the liver in humans. Surg Gynec Obstet. 1963;117:659-676.
23. Suriani RJ, Cutrone A, Cohen E. Pulmonary thromboembolism during liver transplantation: is venovenous bypass protective? (abstract). Liver Transplant Surg. 1995;1:416.
24. Gologorsky E, De Wolf AM, Scott V, et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl. 2001;7:783-789.
25. Schalm SW, Terpstra JL, Achterberg JR, et al. Orthotopic liver transplantation. An experimental study on mechanisms of hemorrhagic diathesis and thrombosis. Surgery. 1975;78:400-507.
26. Groth CG. Changes in coagulation. In: Experience in Hepatic Transplantation. Philadelphia: WB Saunders; 1969:159-175.
27. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method of assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195-202.
28. Eisenberg JM, Clarke JR, Sussman SA. Prothrombin and partial thromboplastin times as preoperative screening tests. Arch Surg. 1982;117:48-51.
29. Velanovich V. The value of routine preoperative laboratory testing in predicting postoperative complications: a multivariate analysis. Surgery. 1991;109:236-243.
30. Gerlach H, Slama KJ, Bechstein WO, et al. Retrospective statistical analysis of coagulation parameters after 250 liver transplantations. Semin Thromb Hemost. 1993;19:223-232.
31. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography- guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88:312-319.
32. Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost. 1995;21(suppl 4):34-44.
33. Mallett SV, Cox DJA. Thromboelastography. BJA. 1992;69:307-313.
34. Zuckerman L, Cohen E, Vagher JP, et al. Comparison of thromboelastography with common coagulation test. Thromb Haemostas. 1981;46:752-756.
35. Gottumukkala VN, Sharma SK, Philip J. Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women. Anesth Analg. 1999;89:1453-1455.
36. Kang YG. Monitoring and treatment of coagulation. In: Winter PM, Kang YG, eds. Hepatic Transplantation: Anesthetic and Perioperative Managemen. New York: Praeger; 1986:151-173.
37. Kang Y, DeWolf A, Aggarwal S, et al. In vitro study on the effects of aprotinin on coagulation during orthotopic liver transplantation. Transplant Proc. 1991;23:1934-1935.
38. Kang Y, Scott V, De Wolf A, et al. In vitro effects of DDAVP during liver transplantation. Transplant Proc. 1993;25:1821-1822.
39. Munoz SJ, Ballas BE, Moritz MJ, et al. Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis. Transplant Proc. 1989;21:3535-3536.
40. Lewis JH, Doyle AP. Effect of epsilon aminocaproic acid on coagulation and fibrinolytic mechanism. JAMA. 1964;188:56-63.
41. Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma. 1997;42:857-861.
42. Azad SC, Kratzer MAA, Groh J, et al. Intraoperative monitoring and postoperative reevaluation of hemostasis in orthotopic liver transplantation. Semin Thromb Hemost. 1993;19:233-237.
43. Ickx B, Pradier O, Degroote F, et al. Effect of two different dosages of aprotinin on perioperative blood loss during liver transplantation. Semin Thromb Hemost. 1993;19:300-301.
44. Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost. 1995;21(suppl 4):34-44.
45. Weber T, Marino IR, Kang YG, et al. Intraoperative blood transfusions in highly immunized patients undergoing orthotopic liver transplantation. Transplantation. 1989;47:797-801.
46. Palareti G, Legagni C, Maccaferri M, et al. Coagulation and fibrinolysis in orthotopic liver transplantation: role of the recipient's disease and use of antithrombin III concentrates. Haemostasis. 1991;21:68-76.
47. McNicol GP, Fletcher AP, Alkjaersig N, et al. The absorption, distribution, and excretion of e-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med. 1962;59:15-24.
48. Kang Y. Coagulation and liver transplantation. Transplant Proc. 1993;25:2001-2005.
49. Rake MO, Flute PT, Parnell G, et al. Intravascular coagulation in acute hepatic necrosis. Lancet. 1970;1:533-537.
50. Carlier M, Veyckemans F, Scholtes JL, et al. Anesthesia for pediatric hepatic transplantation: experience of 33 cases. Transplant Proc. 1987;19:3333-3337.
51. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology. 1996;85:1043-1048.
52. Ickx B, Pradier O, Degroote F, et al. Effect of two different dosages of aprotinin on perioperative blood loss during liver transplantation. Semin Thromb Hemost. 1993;19:300-301.
53. Neuhaus P, Bechstein WO, Lefebre B, et al. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet. 1989;2:924-925.
54. Ickx B, Pierre S, Pradier M, et al. Comparison of two different antifibrinolytic treatment in the prevention of bleeding during orthotopic liver transplantation (abstract). Liver Transplant Surgery. 1995;1:410.
55. Mallett SV, Cox D, Burroughs AK, et al. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation (letter). Lancet. 1990;336:886-887.
56. Riess H. The use of aprotinin in liver transplantation. In: Blood Conservation with Aprotinin. Philadelphia: Hanley & Belfus; 1995:349-358.
57. Groh J, Welte M, Azad SC, et al. Does aprotinin really reduce blood loss in orthotopic liver transplantation? Semin Thromb Haemost. 1993;19:306-308.
58. Himmlreich G, Kierzek B, Neuhaus P, et al. Fibrinolytic changes and the influence of the early perfusate in orthotopic liver transplantation with intraoperative aprotinin treatment. Transplant Proc. 1991;23:1936-1937.
59. Suarez M, Sangro B, Herrero JL, et al. Effectiveness of aprotinin in orthotopic liver transplantation. Semin Thromb Hemost. 1993;19:292-296.
60. Baubillier E, Cherqui D, Dominique C, et al. A fatal thrombotic complication during liver transplantation after aprotonin administration. Transplantation. 1994;57:1664-1666.
61. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of hemophilia and von Willebrand's diseases. Lancet. 1977;1:869-872.
62. Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979;7:107-117.
63. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood. 1986;67:1148-1153.
64. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial. N Engl J Med. 1986;314:1402-1406.
65. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61-S65.